Literature DB >> 23474819

A patient-derived olfactory stem cell disease model for ataxia-telangiectasia.

Romal Stewart1, Sergei Kozlov, Nicholas Matigian, Gautam Wali, Magtouf Gatei, Ratneswary Sutharsan, Bernadette Bellette, Amanda Wraith-Kijas, Julie Cochrane, Mark Coulthard, Chris Perry, Kate Sinclair, Alan Mackay-Sim, Martin F Lavin.   

Abstract

The autosomal recessive disorder ataxia-telangiectasia (A-T) is characterized by genome instability, cancer predisposition and neurodegeneration. Although the role of ataxia-telangiectasia mutated (ATM) protein, the protein defective in this syndrome, is well described in the response to DNA damage, its role in protecting the nervous system is less clear. We describe the establishment and characterization of patient-specific stem cells that have the potential to address this shortcoming. Olfactory neurosphere (ONS)-derived cells were generated from A-T patients, which expressed stem cell markers and exhibited A-T molecular and cellular characteristics that included hypersensitivity to radiation, defective radiation-induced signaling and cell cycle checkpoint defects. Introduction of full-length ATM cDNA into these cells corrected defects in the A-T cellular phenotype. Gene expression profiling and pathway analysis revealed defects in multiple cell signaling pathways associated with ATM function, with cell cycle, cell death and DNA damage response pathways being the most significantly dysregulated. A-T ONS cells were also capable of differentiating into neural progenitors, but they were defective in neurite formation, number of neurites and length of these neurites. Thus, ONS cells are a patient-derived neural stem cell model that recapitulate the phenotype of A-T, do not require genetic reprogramming, have the capacity to differentiate into neurons and have potential to delineate the neurological defect in these patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23474819     DOI: 10.1093/hmg/ddt101

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  12 in total

1.  Patient-derived stem cells: pathways to drug discovery for brain diseases.

Authors:  Alan Mackay-Sim
Journal:  Front Cell Neurosci       Date:  2013-03-27       Impact factor: 5.505

2.  MicroRNA screening identifies a link between NOVA1 expression and a low level of IKAP in familial dysautonomia.

Authors:  Mylène Hervé; El Chérif Ibrahim
Journal:  Dis Model Mech       Date:  2016-06-29       Impact factor: 5.758

3.  Expanding the spectrum of PEX16 mutations and novel insights into disease mechanisms.

Authors:  Kishore R Kumar; Gautam Wali; Ryan L Davis; Amali C Mallawaarachchi; Elizabeth E Palmer; Velimir Gayevskiy; Andre E Minoche; David Veivers; Marcel E Dinger; Alan Mackay-Sim; Mark J Cowley; Carolyn M Sue
Journal:  Mol Genet Metab Rep       Date:  2018-07-20

Review 4.  Patient-Derived Stem Cell Models in SPAST HSP: Disease Modelling and Drug Discovery.

Authors:  Gautam Wali; Carolyn M Sue; Alan Mackay-Sim
Journal:  Brain Sci       Date:  2018-07-31

5.  Increased susceptibility of airway epithelial cells from ataxia-telangiectasia to S. pneumoniae infection due to oxidative damage and impaired innate immunity.

Authors:  Abrey J Yeo; Anna Henningham; Emmanuelle Fantino; Sally Galbraith; Lutz Krause; Claire E Wainwright; Peter D Sly; Martin F Lavin
Journal:  Sci Rep       Date:  2019-02-22       Impact factor: 4.379

Review 6.  Hereditary Spastic Paraplegia: From Genes, Cells and Networks to Novel Pathways for Drug Discovery.

Authors:  Alan Mackay-Sim
Journal:  Brain Sci       Date:  2021-03-22

7.  Motor pathway degeneration in young ataxia telangiectasia patients: A diffusion tractography study.

Authors:  Ishani Sahama; Kate Sinclair; Simona Fiori; James Doecke; Kerstin Pannek; Lee Reid; Martin Lavin; Stephen Rose
Journal:  Neuroimage Clin       Date:  2015-08-20       Impact factor: 4.881

8.  Functional and molecular defects of hiPSC-derived neurons from patients with ATM deficiency.

Authors:  L Carlessi; E Fusar Poli; G Bechi; M Mantegazza; B Pascucci; L Narciso; E Dogliotti; C Sala; C Verpelli; D Lecis; D Delia
Journal:  Cell Death Dis       Date:  2014-07-17       Impact factor: 8.469

Review 9.  ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?

Authors:  Rita Mejzini; Loren L Flynn; Ianthe L Pitout; Sue Fletcher; Steve D Wilton; P Anthony Akkari
Journal:  Front Neurosci       Date:  2019-12-06       Impact factor: 4.677

10.  Altered Secretome and ROS Production in Olfactory Mucosa Stem Cells Derived from Friedreich's Ataxia Patients.

Authors:  Sara Pérez-Luz; Frida Loria; Yurika Katsu-Jiménez; Daniel Oberdoerfer; Oscar-Li Yang; Filip Lim; José Luis Muñoz-Blanco; Javier Díaz-Nido
Journal:  Int J Mol Sci       Date:  2020-09-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.